KR101574642B1 - 항균성 퀴놀린 유도체 - Google Patents

항균성 퀴놀린 유도체 Download PDF

Info

Publication number
KR101574642B1
KR101574642B1 KR1020097012242A KR20097012242A KR101574642B1 KR 101574642 B1 KR101574642 B1 KR 101574642B1 KR 1020097012242 A KR1020097012242 A KR 1020097012242A KR 20097012242 A KR20097012242 A KR 20097012242A KR 101574642 B1 KR101574642 B1 KR 101574642B1
Authority
KR
South Korea
Prior art keywords
alkyl
aryl
compound
het
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020097012242A
Other languages
English (en)
Korean (ko)
Other versions
KR20090090339A (ko
Inventor
제롬 에밀 조르쥬 길레몽
이스멧 도랑쥬
마갈리 마들렌 시몬 모테
코엔라트 요제프 로데윅 마르셀 안드리스
아닐 코울
Original Assignee
얀센 파마슈티카 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37909392&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101574642(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 얀센 파마슈티카 엔.브이. filed Critical 얀센 파마슈티카 엔.브이.
Publication of KR20090090339A publication Critical patent/KR20090090339A/ko
Application granted granted Critical
Publication of KR101574642B1 publication Critical patent/KR101574642B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
KR1020097012242A 2006-12-06 2007-12-04 항균성 퀴놀린 유도체 Active KR101574642B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06125510 2006-12-06
EP06125510.5 2006-12-06

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020157031291A Division KR101908350B1 (ko) 2006-12-06 2007-12-04 항균성 퀴놀린 유도체

Publications (2)

Publication Number Publication Date
KR20090090339A KR20090090339A (ko) 2009-08-25
KR101574642B1 true KR101574642B1 (ko) 2015-12-04

Family

ID=37909392

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020097012242A Active KR101574642B1 (ko) 2006-12-06 2007-12-04 항균성 퀴놀린 유도체
KR1020167037101A Ceased KR20170003741A (ko) 2006-12-06 2007-12-04 항균성 퀴놀린 유도체
KR1020157031291A Active KR101908350B1 (ko) 2006-12-06 2007-12-04 항균성 퀴놀린 유도체

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020167037101A Ceased KR20170003741A (ko) 2006-12-06 2007-12-04 항균성 퀴놀린 유도체
KR1020157031291A Active KR101908350B1 (ko) 2006-12-06 2007-12-04 항균성 퀴놀린 유도체

Country Status (31)

Country Link
US (1) US8293732B2 (https=)
EP (1) EP2099760B1 (https=)
JP (1) JP5466012B2 (https=)
KR (3) KR101574642B1 (https=)
CN (1) CN101547905B (https=)
AP (1) AP2670A (https=)
AR (1) AR064147A1 (https=)
BR (1) BRPI0719939B8 (https=)
CA (1) CA2668517C (https=)
CL (1) CL2007003515A1 (https=)
CY (1) CY1114384T1 (https=)
DK (1) DK2099760T3 (https=)
EA (1) EA022344B1 (https=)
ES (1) ES2407824T3 (https=)
HR (1) HRP20130372T1 (https=)
IL (2) IL199078A (https=)
JO (1) JO2970B1 (https=)
ME (1) ME01521B (https=)
MX (1) MX2009005979A (https=)
MY (1) MY150411A (https=)
NO (1) NO342095B1 (https=)
NZ (1) NZ577128A (https=)
PL (1) PL2099760T3 (https=)
PT (1) PT2099760E (https=)
RS (1) RS52753B (https=)
SG (1) SG10201405650SA (https=)
SI (1) SI2099760T1 (https=)
TW (1) TWI396536B (https=)
UA (1) UA101306C2 (https=)
WO (1) WO2008068268A1 (https=)
ZA (1) ZA200903946B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150126737A (ko) * 2006-12-06 2015-11-12 얀센 파마슈티카 엔.브이. 항균성 퀴놀린 유도체

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104254527B (zh) 2012-04-27 2017-05-31 詹森药业有限公司 抗菌的喹啉衍生物
ES2607879T3 (es) 2012-04-27 2017-04-04 Janssen Pharmaceutica N.V. Derivados de quinolina antibacterianos
BR122023025283A2 (pt) * 2016-03-07 2024-02-20 Global Alliance For Tb Drug Development Inc Compostos antibacterianos e seus usos
US11857352B2 (en) 2016-09-06 2024-01-02 The Research Foundation For The State University Of New York Positron imaging tomography imaging agent composition and method for bacterial infection

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004011436A1 (en) * 2002-07-25 2004-02-05 Janssen Pharmaceutica N.V. Quinoline derivatives and their use as mycobacterial inhibitors
WO2005117875A1 (en) * 2004-05-28 2005-12-15 Janssen Pharmaceutica N.V. Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
WO2006067048A1 (en) * 2004-12-24 2006-06-29 Janssen Pharmaceutica N.V. Quinoline derivatives for the treatment of latent tuberculosis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018326A1 (en) * 1996-10-28 1998-05-07 Department Of The Army, U.S. Government Compounds, compositions and methods for treating antibiotic-resistant infections
US6103905A (en) 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
EA011277B1 (ru) 2004-01-23 2009-02-27 Янссен Фармацевтика Н.В. Производные хинолина и их применение в качестве ингибиторов микобактерий
EA011359B1 (ru) 2004-01-23 2009-02-27 Янссен Фармацевтика Н.В. Замещенные хинолины и их применение в качестве микобактериальных ингибиторов
CA2554049C (en) 2004-01-29 2012-12-18 Janssen Pharmaceutica N.V. Quinoline derivatives for use as mycobacterial inhibitors
PL1797115T3 (pl) 2004-09-28 2017-12-29 Janssen Pharmaceutica N.V. Domena wiążąca bakteryjnej syntazy ATP
CA2528849C (en) 2005-06-08 2014-01-14 Janssen Pharmaceutica N.V. Quinoline derivatives as antibacterial agents
JO2752B1 (en) 2005-06-28 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
KR101329587B1 (ko) 2005-06-28 2013-11-15 얀센 파마슈티카 엔.브이. 항균제로서의 퀴놀린 유도체
JO2683B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2970B1 (en) * 2006-12-06 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004011436A1 (en) * 2002-07-25 2004-02-05 Janssen Pharmaceutica N.V. Quinoline derivatives and their use as mycobacterial inhibitors
WO2005117875A1 (en) * 2004-05-28 2005-12-15 Janssen Pharmaceutica N.V. Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
WO2006067048A1 (en) * 2004-12-24 2006-06-29 Janssen Pharmaceutica N.V. Quinoline derivatives for the treatment of latent tuberculosis

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150126737A (ko) * 2006-12-06 2015-11-12 얀센 파마슈티카 엔.브이. 항균성 퀴놀린 유도체
KR101908350B1 (ko) * 2006-12-06 2018-10-16 얀센 파마슈티카 엔.브이. 항균성 퀴놀린 유도체

Also Published As

Publication number Publication date
PL2099760T3 (pl) 2013-07-31
ME01521B (me) 2014-04-20
JO2970B1 (en) 2016-03-15
IL199078A (en) 2015-10-29
AR064147A1 (es) 2009-03-18
JP2010511669A (ja) 2010-04-15
TW200838530A (en) 2008-10-01
DK2099760T3 (da) 2013-05-13
PT2099760E (pt) 2013-05-06
SG10201405650SA (en) 2014-11-27
WO2008068268A1 (en) 2008-06-12
CY1114384T1 (el) 2016-08-31
MY150411A (en) 2014-01-15
NZ577128A (en) 2012-01-12
AU2007328888A1 (en) 2008-06-12
AP2670A (en) 2013-05-15
EA022344B1 (ru) 2015-12-30
EP2099760A1 (en) 2009-09-16
NO20092536L (no) 2009-08-24
MX2009005979A (es) 2009-06-16
US8293732B2 (en) 2012-10-23
JP5466012B2 (ja) 2014-04-09
KR20150126737A (ko) 2015-11-12
KR20170003741A (ko) 2017-01-09
EA200970536A1 (ru) 2009-10-30
EP2099760B1 (en) 2013-02-20
BRPI0719939A2 (pt) 2014-03-11
HK1137433A1 (en) 2010-07-30
CA2668517A1 (en) 2008-06-12
IL241548B (en) 2018-03-29
TWI396536B (zh) 2013-05-21
CN101547905B (zh) 2015-01-28
CA2668517C (en) 2016-01-12
CL2007003515A1 (es) 2008-07-11
SI2099760T1 (sl) 2013-06-28
IL241548A0 (en) 2015-11-30
UA101306C2 (en) 2013-03-25
BRPI0719939B1 (pt) 2020-11-17
HRP20130372T1 (en) 2013-05-31
AP2009004871A0 (en) 2009-06-30
BRPI0719939B8 (pt) 2021-05-25
NO342095B1 (no) 2018-03-19
ZA200903946B (en) 2010-08-25
KR20090090339A (ko) 2009-08-25
US20100029679A1 (en) 2010-02-04
RS52753B (sr) 2013-08-30
ES2407824T3 (es) 2013-06-14
KR101908350B1 (ko) 2018-10-16
CN101547905A (zh) 2009-09-30

Similar Documents

Publication Publication Date Title
KR101490222B1 (ko) 항균성 퀴놀린 유도체
KR101514992B1 (ko) 항균성 퀴놀린 유도체
KR101526175B1 (ko) 항박테리아 퀴놀린 유도체
KR101574642B1 (ko) 항균성 퀴놀린 유도체
KR101490221B1 (ko) 항박테리아 퀴놀린 유도체
KR101553600B1 (ko) 항균성 퀴놀린 유도체
JP5193858B2 (ja) 抗菌剤としてのキノリン誘導体
AU2007328888B2 (en) Antibacterial quinoline derivatives
HK1137433B (en) Antibacterial quinoline derivatives
HK1124232A1 (zh) 作为抗菌剂的喹啉衍生物
HK1124232B (en) Quinoline derivatives as antibacterial agents
HK1208437B (zh) 抗菌的喹啉衍生物
HK1137435A (en) Antibacterial quinoline derivatives

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20181029

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20191029

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20201028

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20211027

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20221017

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 11